Fiche publication
Date publication
septembre 2018
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
Berriolo-Riedinger A, Becker S, Casasnovas O, Vander Borght T, Édeline V
Lien Pubmed
Résumé
Fluorodeoxyglucose (FDG) positons emission tomography (PET)-computed tomography (CT) is used in many ways at baseline and during the treatment of patients with Hodgkin lymphoma. Many properties of the technique are used in the different steps of patient's management. Initial staging with PET-CT is more accurate than conventional imaging and PET-CT also became the gold standard imaging at the end of treatment with a negative PET-CT mandatory for reaching a complete remission. Early assessment of response by PET-CT is one of the most powerful prognostic factors for progression-free survival of patients with localized and advanced stages and allows guiding treatment. Conversely, previous studies showed that there is no role of FDG PET-CT for the patient's follow-up.
Mots clés
Antineoplastic Agents, therapeutic use, Clinical Decision-Making, Fluorodeoxyglucose F18, Hematopoietic Stem Cell Transplantation, Hodgkin Disease, diagnostic imaging, Humans, Lymph Nodes, diagnostic imaging, Lymphatic Irradiation, Neoplasm Staging, methods, Neoplasm, Residual, diagnostic imaging, Positron Emission Tomography Computed Tomography, Prognosis, Radiopharmaceuticals, Radiotherapy, Image-Guided
Référence
Cancer Radiother. 2018 Sep;22(5):393-400
